77 related articles for article (PubMed ID: 3793856)
1. Testosterone-related exacerbation of a prolactin-producing macroadenoma: possible role for estrogen.
Prior JC; Cox TA; Fairholm D; Kostashuk E; Nugent R
J Clin Endocrinol Metab; 1987 Feb; 64(2):391-4. PubMed ID: 3793856
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study.
Molitch ME; Elton RL; Blackwell RE; Caldwell B; Chang RJ; Jaffe R; Joplin G; Robbins RJ; Tyson J; Thorner MO
J Clin Endocrinol Metab; 1985 Apr; 60(4):698-705. PubMed ID: 3882737
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
4. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
5. Rapid regression of pituitary prolactinomas during bromocriptine treatment.
Thorner MO; Martin WH; Rogol AD; Morris JL; Perryman RL; Conway BP; Howards SS; Wolfman MG; MacLeod RM
J Clin Endocrinol Metab; 1980 Sep; 51(3):438-45. PubMed ID: 6773972
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature.
Sodi R; Fikri R; Diver M; Ranganath L; Vora J
Ann Clin Biochem; 2005 Mar; 42(Pt 2):153-9. PubMed ID: 15829128
[TBL] [Abstract][Full Text] [Related]
7. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Gillam MP; Middler S; Freed DJ; Molitch ME
J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
[TBL] [Abstract][Full Text] [Related]
8. In vivo effects of progestins on prolactin secretion.
Sitruk-Ware R; Varin C; Clair F; Maugis E; Fermanian J; Mauvais-Jarvis P
J Clin Endocrinol Metab; 1985 Mar; 60(3):575-8. PubMed ID: 3919048
[TBL] [Abstract][Full Text] [Related]
9. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
10. Estrogen-induced prolactinoma in a man.
Gooren LJ; Assies J; Asscheman H; de Slegte R; van Kessel H
J Clin Endocrinol Metab; 1988 Feb; 66(2):444-6. PubMed ID: 3339116
[TBL] [Abstract][Full Text] [Related]
11. Return of gonadal function in men with prolactin-secreting pituitary tumors.
Murray FT; Cameron DF; Ketchum C
J Clin Endocrinol Metab; 1984 Jul; 59(1):79-85. PubMed ID: 6427273
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinaemia in males with and without pituitary macroadenomas.
Spark RF; Wills CA; O'Reilly G; Ransil BJ; Bergland R
Lancet; 1982 Jul; 2(8290):129-32. PubMed ID: 6123841
[TBL] [Abstract][Full Text] [Related]
13. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
14. Normal growth and pubertal development during bromocriptine treatment for a prolactin-secreting pituitary macroadenoma.
Dalzell GW; Atkinson AB; Carson DJ; Sheridan B
Clin Endocrinol (Oxf); 1987 Feb; 26(2):169-72. PubMed ID: 3665115
[TBL] [Abstract][Full Text] [Related]
15. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
16. [Effect of tamoxifen on the treatment of pituitary adenomas with bromocriptine].
Yamashita M; Hirakawa T; Tashiro Y; Matsuda T; Kibe M; Fukushima T; Tomonaga M
No Shinkei Geka; 1987 Jan; 15(1):65-72. PubMed ID: 3822068
[TBL] [Abstract][Full Text] [Related]
17. [Bromocriptine therapy of prolactinoma in pregnancy].
Nehmzow M; Ventz M; Meng W
Zentralbl Gynakol; 1985; 107(14):899-903. PubMed ID: 4036407
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.
Kamoi K; Tchuchida I; Sato H; Tanaka R; Ishiguro T; Kaneko K; Iwasaki Y; Shibata A
J Clin Endocrinol Metab; 1981 Dec; 53(6):1285-7. PubMed ID: 7298805
[TBL] [Abstract][Full Text] [Related]
19. Prolactinomas, testosterone-binding globulin, and androgen metabolism.
Vermeulen A; Andó S; Verdonck L
J Clin Endocrinol Metab; 1982 Feb; 54(2):409-12. PubMed ID: 7198651
[TBL] [Abstract][Full Text] [Related]
20. A human pituitary adenoma secreting thyrotropin and prolactin: immunohistochemical, biochemical, and cell culture studies.
Jaquet P; Hassoun J; Delori P; Gunz G; Grisoli F; Weintraub BD
J Clin Endocrinol Metab; 1984 Nov; 59(5):817-24. PubMed ID: 6480809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
